Former Shell Company Registers with SEC, Discloses Going Concern Doubt and Related-Party Revenue Model
BIOM filed a Corporate Governance and Compliance on light trading volume (0.1× avg).
Summary
Biomolecular Life Holdings registered with the SEC, disclosing it recently exited shell status via a related-party marketing deal, has a going concern warning, no cash, and a $3.5M working capital deficit.
Key Events · Corporate Governance and Compliance · BIOM
-
First SEC Registration as Former Shell Company
Company filed Form 10 to register with the SEC, disclosing it exited shell status on July 23, 2026 via a Marketing Services and License Agreement with Biomolecular Life LLC, a related party controlled by sole officer Jessika Contreras.
-
Going Concern Warning and No Cash
Auditor expressed substantial doubt about the company's ability to continue as a going concern. As of March 31, 2026, the company had no cash and a working capital deficit of $3,525,433.
-
Related-Party Revenue Model
The company's only contracted revenue is a 15% fee on Net Revenue from Biomolecular Life LLC product sales. The agreement was not negotiated at arm's length and can be terminated by either party on 30 days' notice.
-
Deep-Discount Convertible Debt
The company has multiple convertible notes with conversion discounts ranging from 25% to 75% of market price, creating a derivative liability of $1,487,202 as of March 31, 2026.
Analysis · BIOM · Life Sciences
Biomolecular Life Holdings filed its first SEC registration statement on Form 10, revealing it only recently exited shell company status through a related-party marketing agreement with Biomolecular Life LLC, an entity controlled by its sole officer and director. The filing discloses a going concern warning from its auditor, a $3.5 million working capital deficit, and a derivative liability of $1.49 million tied to deeply discounted convertible notes. The company has no cash, no revenue, and its only contracted income source is a 15% fee on sales by a related party that can terminate the agreement on 30 days' notice. This is the first time investors can see the full picture of the company's financial distress and governance structure.
How filings like this one have moved
In the 30 days to Aug 26, 2026, 37.4% of the 3468 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BIOM was trading at $0.45 on OTC in the Life Sciences sector, with a market capitalization of approximately $474.6K. The 52-week trading range was $0.02 to $2.25. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.